Anti-Ku Antibodies: Clinical Associations, Organ Damage, and Prognostic Implications in Connective Tissue Diseases
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26157433 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Céline La und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hôpital Erasme, Hôpital Universitaire de Bruxelles (HUB), 1070 Bruxelles, Belgium. Hauptthemen laut MEDLINE: Connective Tissue Diseases, Autoantibodies, Ku Autoantigen, Antibodies, Antinuclear. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Rheumatology of HUB.
Abstract (Originalsprache)
Anti-Ku antibodies are rare autoantibodies associated with connective tissue diseases (CTDs), but their clinical significance remains poorly understood due to limited studies. Semi-quantitative immunodot assays yield positive, negative, or borderline results, with the clinical relevance of borderline findings remaining unclear. The purpose of this study is to characterize the clinical spectrum of anti-Ku-positive patients and evaluate the clinical significance of anti-Ku-borderline results in CTD management. A retrospective cohort study was conducted at Hôpital Erasme, including all patients with anti-Ku-positive or borderline results, over a 10-year period. Clinical and biological data were collected from medical records and analyzed for disease associations, organ involvement, and outcomes. Among 47 anti-Ku-positive patients, systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS) were the most common diagnoses. Interstitial lung disease (ILD) occurred in 23.4% and renal involvement in 12.8% of patients. Cytopenia was significantly associated with glomerulonephritis. Organ damage, particularly pulmonary and renal involvement, correlated with increased mortality. In the borderline group (n = 33), SLE and SS remained the predominant diagnoses. During follow-up, three patients died (all with isolated ILD without associated CTD), one required chronic dialysis, and one underwent lung transplantation. ILD was present in 7/22 (31.8%) borderline patients, and renal involvement in 7/32 (21.9%). This study demonstrates significant associations between anti-Ku antibodies and organ damage, with increased mortality risk. The high prevalence of pulmonary and renal involvement in anti-Ku-borderline patients suggests that these results carry substantial clinical significance and should prompt comprehensive CTD evaluation. These findings support treating borderline anti-Ku results with the same clinical vigilance as positive results, given their similar association with severe organ involvement and adverse outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Hôpital Erasme, Hôpital Universitaire de Bruxelles (HUB), 1070 Bruxelles, Belgium.
- Laboratory of Immunology, Laboratoire Hospitalier Universitaire de Bruxelles, Université Libre de Bruxelles (LHUB-ULB), 1020 Bruxelles, Belgium.
ORCID-Profile: Céline La, Carole Nagant, Muhammad Soyfoo
Förderung
- Department of Rheumatology of HUB
Zitieren
APA
La, C., Smet, J., Nagant, C., & Soyfoo, M. (2025). Anti-Ku Antibodies: Clinical Associations, Organ Damage, and Prognostic Implications in Connective Tissue Diseases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157433
Vancouver
La C, Smet J, Nagant C, Soyfoo M. Anti-Ku Antibodies: Clinical Associations, Organ Damage, and Prognostic Implications in Connective Tissue Diseases. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157433
BibTeX
@article{La2025,
author = {La, Céline and Smet, Julie and Nagant, Carole and Soyfoo, Muhammad},
title = {Anti-Ku Antibodies: Clinical Associations, Organ Damage, and Prognostic Implications in Connective Tissue Diseases},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26157433}
}
EUVIMED